A systematic review of the effect of semaglutide on lean mass: insights from clinical trials

References

• World_Obesity_Atlas_2022.
   Google Scholar
• Yumuk V, Tsigos C, Fried M, et al. European Guidelines for Obesity Management in Adults. Obes Facts. 2015;8(6):402–424. doi: 10.1159/000442721
   PubMed Web of Science ®Google Scholar
• Prospective Studies Collaboration. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373:1083–1096. doi: 10.1016/S0140-6736(09)60318-4
   PubMed Web of Science ®Google Scholar
• World Health Organization. A healthy lifestyle - WHO recommendations. 2010. https://www.who.int/europe/news-room/fact-sheets/item/a-healthy-lifestyle---who-recommendations
   Google Scholar
• Velazquez A, Apovian CM. Updates on obesity pharmacotherapy. Ann N Y Acad Sci. 2018;1411:106–119. doi: 10.1111/nyas.13542
   PubMed Web of Science ®Google Scholar
• Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019;15(5):288–298. doi: 10.1038/s41574-019-0176-8
   PubMed Web of Science ®Google Scholar
• Chao AM, Tronieri JS, Amaro A, et al. Semaglutide for the treatment of obesity. Trends Cardiovasc Med. 2023;33:159–166. doi: 10.1016/j.tcm.2021.12.008
   PubMed Web of Science ®Google Scholar
• Tsapas A, Karagiannis T, Kakotrichi P, et al. Comparative efficacy of glucose‐lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta‐analysis. Diab Obes Metab. 2021;23:2116–2124. doi: 10.1111/dom.14451
   PubMed Web of Science ®Google Scholar
• Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes. Diabetes Care. 2009;32(1):84–90. doi: 10.2337/dc08-1355
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists. Diabet Res Clin Pract. 2018;143:88–100. doi: 10.1016/j.diabres.2018.06.008
   PubMed Web of Science ®Google Scholar
• Holst JJ, Madsbad S. Semaglutide seems to be more effective the other GLP-1Ras. Ann Transl Med. 2017;505–505. doi: 10.21037/atm.2017.11.10
   PubMed Web of Science ®Google Scholar
• Amaro A, Sugimoto D, Wharton S. Efficacy and safety of semaglutide for weight management: evidence from the STEP program. Postgrad Med. 2022;134:5–17. doi: 10.1080/00325481.2022.2147326
   PubMed Web of Science ®Google Scholar
• Ghusn W, De la Rosa A, Sacoto D, et al. Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity. JAMA Netw Open. 2022;5(9):e2231982. doi: 10.1001/jamanetworkopen.2022.31982
   PubMed Web of Science ®Google Scholar
• Meier JJ. Efficacy of Semaglutide in a subcutaneous and an oral formulation. Front Endocrinol. 2021;12. doi: 10.3389/fendo.2021.645617
   Web of Science ®Google Scholar
• Frisch S, Zittermann A, Berthold HK, et al. A randomized controlled trial on the efficacy of carbohydrate-reduced or fat-reduced diets in patients attending a telemedically guided weight loss program. Cardiovasc Diabetol. 2009;8(1):36. doi: 10.1186/1475-2840-8-36
   PubMedGoogle Scholar
• Kim B, Tsujimoto T, So R, et al. Changes in muscle strength after diet-induced weight reduction in adult men with obesity: a prospective study. Diabetes Metab Syndr Obes. 2017;10:187–194. doi: 10.2147/DMSO.S132707
   PubMed Web of Science ®Google Scholar
• Zembura M, Czepczor-Bernat K, Dolibog P, et al. Skeletal muscle mass, muscle strength, and physical performance in children and adolescents with obesity. Front Endocrinol. 2023;14. doi: 10.3389/fendo.2023.1252853
   Web of Science ®Google Scholar
• Fukuoka Y, Narita T, Fujita H, et al. Importance of physical evaluation using skeletal muscle mass index and body fat percentage to prevent sarcopenia in elderly Japanese diabetes patients. J Diabetes Investig. 2019;10:322–330. doi: 10.1111/jdi.12908
   PubMed Web of Science ®Google Scholar
• Yang Jinzeng. Chapter Five - Enhanced Skeletal Muscle for Effective Glucose Homeostasis. Progress in Molecular Biology and Translational Science. 2014;121:133–163. doi: 10.1016/B978-0-12-800101-1.00005-3
   Google Scholar
• Nomura T, Kawae T, Kataoka H, et al. Assessment of lower extremity muscle mass, muscle strength, and exercise therapy in elderly patients with diabetes mellitus. Environ Health Prev Med. 2018;23(1):20. doi: 10.1186/s12199-018-0710-7
   PubMed Web of Science ®Google Scholar
• Ishii S, Nagai Y, Sada Y, et al. Liraglutide reduces visceral and intrahepatic fat without significant loss of muscle mass in obese patients with type 2 diabetes: a prospective case series. J Clin Med Res. 2019;11(3):219–224. doi: 10.14740/jocmr3647
   PubMedGoogle Scholar
• Greenhalgh T, Peacock R. Effectiveness and efficiency of search methods in systematic reviews of complex evidence: audit of primary sources. BMJ. 2005;331(7524):1064–1065. doi: 10.1136/bmj.38636.593461.68
   PubMed Web of Science ®Google Scholar
• Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. doi: 10.1056/NEJMoa2032183
   PubMed Web of Science ®Google Scholar
• Blundell J, Finlayson G, Axelsen M, et al. Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diab Obes Metab. 2017;19:1242–1251. doi: 10.1111/dom.12932
   PubMed Web of Science ®Google Scholar
• McCrimmon RJ, Catarig A-M, Frias JP, et al. Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial. Diabetologia. 2020;63:473–485. doi: 10.1007/s00125-019-05065-8
   PubMed Web of Science ®Google Scholar
• Volpe S, Lisco G, Fanelli M, et al. Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study. Front Endocrinol. 2023;14. doi: 10.3389/fendo.2023.1240263
   PubMed Web of Science ®Google Scholar
• Gibbons C, Blundell J, Tetens Hoff S, et al. Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes. Diab Obes Metab. 2021;23:581–588. doi: 10.1111/dom.14255
   PubMed Web of Science ®Google Scholar
• Volpe S, Lisco G, Racaniello D, et al. Once-weekly semaglutide induces an early improvement in body composition in patients with type 2 diabetes: a 26-week prospective real-life study. Nutrients. 2022;14(12):2414. doi: 10.3390/nu14122414
   PubMed Web of Science ®Google Scholar
• Bazzocchi A, Ponti F, Albisinni U, et al. DXA: Technical aspects and application. Eur J Radiol. 2016;85(8):1481–1492. doi: 10.1016/j.ejrad.2016.04.004
   PubMed Web of Science ®Google Scholar
• Shuster A, Patlas M, Pinthus JH, et al. The clinical importance of visceral adiposity: a critical review of methods for visceral adipose tissue analysis. Br J Radiol. 2012;85:1–10. doi: 10.1259/bjr/38447238
   PubMed Web of Science ®Google Scholar
• Ritchie SA, Connell JMC. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr Metab Cardiovasc Dis. 2007;17(4):319–326. doi: 10.1016/j.numecd.2006.07.005
   PubMed Web of Science ®Google Scholar
• Busetto L. Visceral obesity and the metabolic syndrome: effects of weight loss. Nutr Metab Cardiovasc Dis. 2001;11(3): 195–204. Cited: in: PMID: 11590996.
   PubMed Web of Science ®Google Scholar
• Gabery S, Salinas CG, Paulsen SJ, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020;5(6). doi: 10.1172/jci.insight.133429
   PubMed Web of Science ®Google Scholar
• Cawthon CR, Blonde GD, Nisi AV, et al. Chronic Semaglutide treatment in rats leads to daily excessive concentration-dependent sucrose intake. J Endocr Soc. 2023;7(7). doi: 10.1210/jendso/bvad074
   PubMed Web of Science ®Google Scholar
• Zhao X, Wang M, Wen Z, et al. GLP-1 receptor agonists: beyond their pancreatic effects. Front Endocrinol. 2021;12. doi: 10.3389/fendo.2021.721135
   Google Scholar
• Dong Y, Carty J, Goldstein N, et al. Time and metabolic state-dependent effects of GLP-1R agonists on NPY/AgRP and POMC neuronal activity in vivo. Mol Metab. 2021;54:101352. doi: 10.1016/j.molmet.2021.101352
   PubMed Web of Science ®Google Scholar
• Klair N, Patel U, Saxena A, et al. What is best for weight loss? A comparative review of the safety and efficacy of bariatric surgery versus glucagon-like peptide-1 analogue. Cureus. 2023. doi: 10.7759/cureus.46197
   Web of Science ®Google Scholar
• Weiss EP, Jordan RC, Frese EM, et al. Effects of weight loss on lean mass, strength, bone, and aerobic capacity. Med Sci Sports Exerc. 2017;49:206–217. doi: 10.1249/MSS.0000000000001074
   PubMedGoogle Scholar
• Silver HJ, Olson D, Mayfield D, et al. Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes. Diab Obes Metab. 2023;25(8):2340–2350. doi: 10.1111/dom.15113
   PubMed Web of Science ®Google Scholar
• Phillips SM, Chevalier S, Leidy HJ. Protein “requirements” beyond the RDA: implications for optimizing health. Appl Physiol Nutr Metab. 2016;41:565–572. doi: 10.1139/apnm-2015-0550
   PubMed Web of Science ®Google Scholar
• Leidy HJ, Hoertel HA, Douglas SM, et al. A high‐protein breakfast prevents body fat gain, through reductions in daily intake and hunger, in “Breakfast skipping” adolescents. Obesity. 2015;23(9):1761–1764. doi: 10.1002/oby.21185
   PubMed Web of Science ®Google Scholar
• Miller CT, Fraser SF, Levinger I, et al. The effects of exercise training in addition to energy restriction on functional capacities and body composition in obese adults during weight loss: a systematic review. PLOS ONE. 2013;8(11):e81692. doi: 10.1371/journal.pone.0081692
   PubMed Web of Science ®Google Scholar
• Moon J, Koh G. Clinical evidence and mechanisms of high-protein diet-induced weight loss. J Obes Metab Syndr. 2020;29:166–173. doi: 10.7570/jomes20028
   PubMed Web of Science ®Google Scholar
• Conway B, Rene A. Obesity as a disease: no lightweight matter. Obesity Rev. 2004;5(3):145–151. doi: 10.1111/j.1467-789X.2004.00144.x
   PubMedGoogle Scholar
• Kolotkin RL, Meter K, Williams GR. Quality of life and obesity. Obesity Rev. 2001;2(4):219–229. doi: 10.1046/j.1467-789X.2001.00040.x
   PubMedGoogle Scholar
• Heymsfield SB, Gonzalez MCC, Shen W, et al. Weight loss composition is one‐fourth fat‐free mass: a critical review and critique of this widely cited rule. Obesity Rev. 2014;15(4):310–321. doi: 10.1111/obr.12143
   PubMed Web of Science ®Google Scholar
• Cava E, Yeat NC, Mittendorfer B. Preserving healthy muscle during weight loss. Adv Nutr. 2017;8(3):511–519.
   PubMed Web of Science ®Google Scholar
• Dodds R, Sayer AA. Sarcopenia and frailty: new challenges for clinical practice. Clin Med. 2016;16(5):455–458. doi: 10.7861/clinmedicine.16-5-455
   PubMed Web of Science ®Google Scholar
• Elkind-Hirsch KE, Chappell N, Shaler D, et al. Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study. Fertil Steril. 2022;118:371–381. doi: 10.1016/j.fertnstert.2022.04.027
   PubMed Web of Science ®Google Scholar
• Choi KM. Sarcopenia and sarcopenic obesity. Korean J Intern Med. 2016;31(6):1054–1060. doi: 10.3904/kjim.2016.193
   PubMed Web of Science ®Google Scholar
• Sharples AP, Hughes DC, Deane CS, et al. Longevity and skeletal muscle mass: the role of IGF signalling, the sirtuins, dietary restriction and protein intake. Aging Cell. 2015;14(4):511–523. doi: 10.1111/acel.12342
   PubMed Web of Science ®Google Scholar
• Kanoski SE, Hayes MR, Skibicka KP. GLP-1 and weight loss: unraveling the diverse neural circuitry. Am J Physiol Regul Integr Comp Physiol. 2016;310:R885–R895. doi: 10.1152/ajpregu.00520.2015
   PubMed Web of Science ®Google Scholar
• Health.gov. Appendix E-3.1.A4. Nutritional goals for each age/sex group used in assessing adequacy of USDA food patterns at various calorie levels; 2015. https://health.gov/our-work/nutrition-physical-activity/dietary-guidelines/previous-dietary-guidelines/2015/advisory-report/appendix-e-3/appendix-e-31a4.
   Google Scholar
• Wolfe Robert R. The underappreciated role of muscle in health and disease [Internet]. The American Journal of Clinical Nutrition; 2006 [cited 2024 Mar 20]. doi: 10.1093/ajcn/84.3.475
   Google Scholar